It was previously reported that constitutive RNASEH2A overexpression protected LNCaP prostate cancer cells against CPT or etoposide [34] and that RNase H2 depletion increased HU sensitivity in HeLa cells [15]. Here, RNASEH2A is linked to prostate carcinoma.